Patterns of Thyroid Radioiodine Uptake: Jordanian Experience

Kusai M. Al-Muqbel1 and Reema M. Tashtoush2

1Department of Radiology and Nuclear Medicine, School of Medicine, Jordan University of Science and Technology, Irbid, Jordan; and 2Endocrinology Clinics, King Abdullah University Hospital, Irbid, Jordan

This study aimed to determine the reference range of 24-h radioiodine uptake in euthyroid Jordanians, as well as the reference ranges for patients with diffuse and nodular hyperthyroidism. In addition, radioiodine uptake ranges were determined for those patients with Hashimoto’s thyroiditis and early-phase subacute thyroiditis. Methods: The medical records of 285 Jordanian patients referred for 131I thyroid scintiscans and 24-h radioiodine uptake tests were reviewed. The patients were referred because of a presumed thyroid disorder. The patients included those who were euthyroid or who had Graves’ disease, toxic nodules, Hashimoto’s thyroiditis, or subacute thyroiditis. Mean radioiodine uptake and the 95% confidence interval were determined in each group. A comparison was made between groups. Results: Mean uptake (±SD) for the euthyroid group, toxic-nodule group, and Hashimoto’s thyroiditis group was 15% ± 7%, 19% ± 9%, and 19% ± 15%, respectively, and these values were not significantly different from each other (P > 0.05). Mean uptake for the subacute thyroiditis group and Graves’ disease group was 3% ± 4% and 40% ± 14%, respectively, and both values were significantly different from other groups (P < 0.05). Conclusion: The reference range of radioiodine uptake in Jordan is comparable to that reported in North America and Europe because Jordanians likely have a sufficient daily intake of stable iodine. Radioiodine uptake discriminates between euthyroid patients, subacute thyroiditis patients, and Graves’ disease patients. Radioiodine uptake in toxic-nodule patients is diagnostic only if combined with image findings. Mean radioiodine uptake in Hashimoto’s thyroiditis is higher than the euthyroid mean but has a wide range.

Key Words: endocrinology; radiopharmaceuticals; CNMT; radioiodine; thyroid; uptake

DOI: 10.2967/jnmt.109.069146

Measurement of thyroid radioiodine uptake is a commonly performed test in daily nuclear medicine practice. Although the utility of thyroid scintiscans and radioiodine uptake measurement is limited for defining the cause of thyrotoxicosis in North America and Europe (1,2), this test is widely used in Jordan to investigate thyroid disorders. Radioiodine uptake is influenced by stable iodine intake, which affects the body iodine pool (3,4). Geographic variation in iodine intake necessitates determination of the local reference range of radioiodine uptake (5). Although every nuclear medicine laboratory is responsible for establishing its own reference radioiodine uptake range, this range was determined in North America in the 1970s (6–12) and in Europe later (13). However, there is no reported reference radioiodine uptake range in the literature in Jordan or elsewhere in the Middle East to rely on. In addition, the literature lacks any reported radioiodine uptake range in diffuse and nodular hyperthyroidism or in Hashimoto’s thyroiditis in the Middle East, including Jordan. This study aimed to determine the reference range of radioiodine uptake in euthyroid Jordanians and the reference ranges for patients with diffuse and nodular hyperthyroidism, patients with Hashimoto’s thyroiditis, and patients with early-phase subacute thyroiditis.

MATERIALS AND METHODS

Patients

The medical records of 285 patients referred for 131I thyroid scintiscans and 24-h radioiodine uptake tests at King Abdullah University Hospital from November 7, 2004, through September 11, 2008, were reviewed. Patients were referred because of a presumed thyroid disorder. The final diagnosis of each patient was determined by the referring physician on the basis of all or part of the following: symptoms, physical examination, serial thyroid function test, ultrasonography, thyroid antibodies, and thyroid scintiscan. The patients were followed for at least 4 mo before the final diagnosis was determined, and they included those who were euthyroid or who had Graves’ disease, toxic nodules, Hashimoto’s thyroiditis, or subacute thyroiditis. The euthyroid group had normal thyroid function at the time of uptake measurement and one or more of the following: normal thyroid findings on scintiscans or ultrasound, a diffuse goiter, a multinodular goiter, a cold or hot nodule, and positive or negative findings for thyroid antibodies. The subacute thyroiditis group had transient thyrotoxicosis (suppressed thyroid-stimulating hormone at the time of the uptake measurement) with spontaneous recovery or development of spontaneous hypothyroidism on follow-up. All subacute thyroiditis patients underwent thyroid scintiscans and
radioiodine uptake measurement within 1–4 wk of onset of thyrotoxic symptoms. The Hashimoto’s thyroiditis group had chronic hypothyroidism (high level of thyroid-stimulating hormone at the time of uptake measurement) and high thyroid peroxidase regardless of whether the patients had a goiter. The toxic-nodule group had hyperthyroidism (suppressed thyroid-stimulating hormone at the time of uptake measurement) with a multinodular goiter or a single toxic nodule. The Graves’ disease group had hyperthyroidism (suppressed thyroid-stimulating hormone at the time of uptake measurement) with diffuse goiter. None of these patients had thyroid surgery or radioiodine ablation before undergoing thyroid scintiscans and radioiodine uptake measurement. The patients were asked to stop taking antithyroid medications, if any, for at least 1 wk before undergoing the thyroid scintiscans and radioiodine uptake measurement. The patients were also asked to stop taking thyroid hormone supplement available in Jordan (1 mo before undergoing the thyroid scintiscans and radioiodine uptake measurement.

**Thyroid Scintiscans**

Twenty-four hours after oral administration of a 1.85- to 3.7-MBq (50- to 100-μCi) 131I capsule, 5-min static thyroid images were obtained in anterior, right anterior oblique, and left anterior oblique views while the patient was supine with the neck extended. Images were obtained by a large-field-of-view γ-camera (E.CAM; Siemens) fitted with a pinhole collimator. Image data were recorded on a 128 × 128 computer matrix.

**Thyroid Radioiodine Uptake Measurement**

Twenty-four hours after dose administration, radioiodine uptake was measured with a thyroid probe (Atomlab 950; Biodex Medical Systems). Patients were seated facing the detector, which was positioned 25 cm from the anterior surface of the patient’s neck at the level of the cricoid. Counts were obtained at the patient’s neck for 1 min and at the patient’s thigh for 1 min. The administered capsule was placed 25 cm from the detector and counted for 1 min just before administration. A phantom was not used. The radioiodine uptake was calculated using the following relationship: Radioiodine uptake = [(neck counts [cpm] − thigh counts [cpm])/administered counts [cpm] − background counts [cpm]]) × 100%.

**RESULTS**

The characteristics of the patient groups are summarized in Table 1. Generally, thyroid disorders are more common in women than men, and most of the patients are middle-aged. The mean uptake values for the euthyroid group, toxic-nodule group, and Hashimoto’s thyroiditis group were 15% ± 7%, 19% ± 9%, and 19% ± 15%, respectively. There was no significant statistical difference between mean uptake values for these 3 groups (P > 0.5). However, both the euthyroid and the toxic-nodule groups had a narrow 95% confidence interval (CI), whereas the Hashimoto’s thyroiditis group had a wide 95% CI (Fig. 1).

The mean uptake value for the subacute thyroiditis group was 3% ± 4%, with a narrow 95% CI, and was statistically different from all other groups (P < 0.05) (Fig. 1). The mean uptake value for Graves’ disease was 40% ± 14%, with a narrow 95% CI, and was statistically different from all other groups (P < 0.05) (Fig. 1). Scatter of the actual radioiodine uptake values for all subjects is shown in Figure 2.

Four euthyroid patients had extremely low radioiodine uptake (<5%). Two of those 4 patients (2% and 3% uptake) underwent contrast CT 1 d before uptake measurement. One also had too many cold nodules as part of a multinodular goiter. The third patient (4% uptake) was in early recovery from recent subacute thyroiditis. Regarding the fourth patient (4% uptake), we failed to find a cause for his low uptake value.

**DISCUSSION**

Thyroid scintiscans and radioiodine uptake measurement are performed more commonly in Europe than in the United States (2). This test is used mainly to identify the cause of thyrotoxicosis (1). In Jordan, this test is widely used for assessment of thyroid disorders, including thyrotoxicosis, nodule characterization, and Hashimoto’s thyroiditis. Although 123I has better spatial resolution and less radioactive burden to the patient than 131I, 123I is not used in Jordan or, probably, in many other developing countries because as a cyclotron product its availability is limited (13). Instead, 131I is widely used in Jordan and in many other developing countries for thyroid scintiscans and radioiodine uptake measurement because its long half-life (8.1 d) and low price make it widely available in most nuclear medicine laboratories in this region of the world.

**TABLE 1**

Means and Ranges of Radioiodine Uptake in Jordanian Patients

<table>
<thead>
<tr>
<th>Group</th>
<th>Total</th>
<th>Mean age (y)</th>
<th>Age range (y)</th>
<th>F</th>
<th>M</th>
<th>F/M ratio</th>
<th>Uptake mean ± SD (%)</th>
<th>Uptake range (%)</th>
<th>Uptake 95% CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euthyroid</td>
<td>102</td>
<td>42.1</td>
<td>17–72</td>
<td>77</td>
<td>25</td>
<td>3.1</td>
<td>15 ± 7</td>
<td>2–56</td>
<td>13–16</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td>108</td>
<td>37.7</td>
<td>16–80</td>
<td>70</td>
<td>38</td>
<td>1.8</td>
<td>40 ± 14</td>
<td>14–90</td>
<td>37–43</td>
</tr>
<tr>
<td>Toxic-nodule</td>
<td>34</td>
<td>54.8</td>
<td>29–81</td>
<td>25</td>
<td>9</td>
<td>2.7</td>
<td>19 ± 9</td>
<td>6–38</td>
<td>15–22</td>
</tr>
<tr>
<td>Hashimoto’s thyroiditis</td>
<td>20</td>
<td>35</td>
<td>14–57</td>
<td>17</td>
<td>3</td>
<td>5.6</td>
<td>19 ± 15</td>
<td>0–64</td>
<td>12–26</td>
</tr>
<tr>
<td>Subacute thyroiditis</td>
<td>21</td>
<td>38.9</td>
<td>21–69</td>
<td>13</td>
<td>8</td>
<td>1.6</td>
<td>3 ± 4</td>
<td>0–14</td>
<td>0–4</td>
</tr>
</tbody>
</table>

*P > 0.5 vs. each other.

1P < 0.05 vs. other groups.
radioiodine uptake measurement (3). In Jordan, nuclear physicians frequently are asked by clinicians what the reference range of radioiodine uptake is. There is no reported reference range for radioiodine uptake in euthyroid subjects in our laboratory was 15% ± 7%, with a narrow 95% CI (13%–16%). Our euthyroid mean is comparable to means reported in the 1970s in North America (6–11) and in later studies using 131I in Europe (12). But our euthyroid mean is smaller than the mean reported in one study that used 123I in the early 1990s in Boston (17).

The nuclear medicine laboratory at King Abdullah University Hospital is the only nuclear medicine facility in northern Jordan at this time. Patients referred to us are coming from urban regions, rural regions, refugee camps, mountainous regions, and desert. Regardless of this variation in the geographic regions of our population within the northern Jordanian districts, we think that our population has sufficient stable iodine intake for 2 reasons: like developed countries, Jordan adds a stable iodine supplement to table salt, and Jordan and other middle east countries have a high consumption of iodine-rich food, including bread, dairy products, seafood, eggs, and vitamin supplements (6,10,11,17). Our euthyroid subjects were not selected from a healthy population. They were patients referred for investigation of a potential thyroid disorder. However, we believe that this is a realistic means of estimating thyroid radioiodine uptake in euthyroid subjects in this region.

The mean thyroid radioiodine uptake in our patients with Graves’ disease was 40% ± 14% with a narrow 95% CI (37%–43%). As noted in other series (4), there is virtually no overlap between uptake ranges in euthyroid groups and Graves’ disease groups. The mean thyroid radioiodine uptake in the subacute thyroiditis group was 3% ± 4%, with a narrow 95% CI (0%–4%). Our data showed no significant overlap between the range of radioiodine uptake in the euthyroid group and the subacute thyroiditis group in northern Jordan, as has also been noted in other series (18). It appears that radioiodine uptake testing discriminated between Graves’ disease and subacute thyroiditis in our population. However, although no significant overlap exists between the uptake ranges of the Graves’, subacute thyroiditis, and euthyroid groups, there is some overlap in actual measured uptake values between these groups as noted in many other nuclear medicine laboratories. In toxic nodular hyperthyroidism, however, this may not be the case because the mean thyroid radioiodine uptake was 19% ± 9% and the range (95% CI of 15%–22%) overlapped both the euthyroid group range and the Hashimoto’s thyroiditis

FIGURE 1. Ranges (95% CI) and mean values of radioiodine uptake in Jordanian patient groups.
The mean thyroid radioiodine uptake in the Hashimoto’s thyroiditis group was 19% ± 15%, with a wide 95% CI (12%–26%). The Hashimoto’s thyroiditis group mean was slightly higher than the euthyroid mean. The Hashimoto’s thyroiditis group range overlapped both the euthyroid group range and the toxic-nodule group range. It has been reported that Hashimoto’s thyroiditis may cause high or low uptake (13,19). One study showed that the most common finding in Hashimoto’s thyroiditis is an enlarged gland with diffusely increased uptake, a pattern identical to that found in Graves’ disease (20). The high avidity for radioiodine reflects chronic stimulation of a failing thyroid gland by thyroid-stimulating hormone in an attempt to produce sufficient thyroid hormone for the body’s needs (20). The response of thyroid follicular cells to endogenous thyroid-stimulating hormone is preserved in thyroiditis patients, and sodium iodide symporter function is suppressed by certain cytokines (13). In addition, it was found that Hashimoto’s thyroiditis affects the intrathyroidal organification of iodine and is one of the most common causes of positive results on perchlorate discharge testing (13,20–22).

In this connection, we admit that several patients in our laboratory underwent 131I thyroid scintiscans and radioiodine uptake measurement with no clear indication for these tests and that, consequently, there was no realistic justification for the subsequent high thyroid radioactive burden in those patients. The main reason for such misuse of this test in Jordan is the unawareness of referring physicians (mostly primary care physicians and general surgeons) about the updated indications for this test. From the nuclear medicine side, we could not cancel the test because cancellation likely will be misunderstood from both the patient side and the referring physician side. However, this type of practice has changed over the last few years in Jordan and referrals have become more realistic. Now we see fewer referrals for euthyroid patients and Hashimoto’s thyroiditis patients unless there is a nodule.

CONCLUSION

The reference range for 24-h radioiodine uptake in Jordan is comparable to that reported in North America and Europe because Jordanians likely have a sufficient daily intake of stable iodine. According to our experience in Jordan, radioiodine uptake discriminates between euthyroid patients, subacute thyroiditis patients, and Graves’ disease patients. Radioiodine uptake in toxic-nodule patients was diagnostic only if combined with image findings. Mean radioiodine uptake in Hashimoto’s thyroiditis was

**FIGURE 2.** Scatter of actual radioiodine uptake values for Jordanian patient groups.
higher than the euthyroid mean, but its range was wide and overlapped with the euthyroid and toxic-nodule ranges.

REFERENCES

Patterns of Thyroid Radioiodine Uptake: Jordanian Experience

Kusai M. Al-Muqbel and Reema M. Tashtoush

Published online: February 16, 2010.
Doi: 10.2967/jnmt.109.069146

This article and updated information are available at:
http://tech.snmjournals.org/content/38/1/32

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://tech.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNMT can be found at:
http://tech.snmjournals.org/site/subscriptions/online.xhtml